![]() The story about NDMA contamination in Zantac/ranitidine batches might not have come to light but for the efforts of a small, start-up pharmacy laboratory in New Haven, Connecticut. Valisure and Detection of NDMA in Ranitidine In 2018, Zantac ranked as one of the top-10 antacid tablets in the United States. Although brand name sales of Zantac declined once generics came on the market, the drug itself continued to propel strong sales. ![]() Zantac became available over-the-counter (OTC) in 1996 and soon thereafter was made available as a generic. Zantac did not disappoint and Glaxo reached $1 billion in sales by December 1986 making the drug one of the most successful runaway hits in the industry. Food and Drug Administration (FDA) in 1983.īeginning in the 1980s, Zantac was sold and distributed in prescription format accompanied by one of the industry’s (then) most ambitious marketing programs. It was developed in 1976 by researcher John Bradshaw and submitted by Glaxo Holdings (now GlaxoSmithKline) for approval by the U.S. H2 Blockers are frequently used to treat gastric ulcers, heartburn, acid indigestion, and other related gastrointestinal conditions. Zantac (named generically as ranitidine) belongs to a class of medications known as H2-receptor antagonists (“H2 Blockers”) which act to lower the level of acid produced in the stomach. Several of those cases have now been consolidated into multidistrict litigation now taking place in a federal court in Florida. ![]() Updated SeptemSince 2019, hundreds of patients have come forward to file claims in court alleging that the popular heartburn medication, Zantac (ranitidine) was contaminated with harmful carcinogenic compounds and that the contaminated medication caused them to develop a variety of dangerous cancers.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |